The study, conducted by the Mayo Clinic, Johns Hopkins School of Medicine and medical device manufacturer TYRX, found patients with cardiac device-associated infections had triple the length of hospital stay, 55-118 percent higher hospitalization costs, 8-11 times the rate of in-hospital mortality and twice the mortality a year after admission compared to patients implanted with a pacemaker or defibrillator who did not contract an infection.
Read the TYRX release on infections associated with cardiac devices (pdf).
Read more coverage on infection control:
– CDC Updates Bloodstream Infection Prevention Guidelines
– Hospital Nabs Top Recognition Despite Criticism for High Infection Rates, Fraud
– Dr. Edo McGowan Responds to Study Indicating MRSA Infection May Be Seasonal
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
